Form 4: Ionis Pharmaceuticals Executive Richard S. Geary Reports Stock Purchase

Richard S. Geary, EVP and Chief Development Officer of Ionis Pharmaceuticals, reports the purchase of 415 shares of common stock at $28.2115 per share through the company's employee stock purchase plan.

Summary

• On February 28, 2025, Richard S. Geary, EVP and Chief Development Officer of Ionis Pharmaceuticals, purchased 415 shares of Ionis Pharmaceuticals common stock.
• The purchase was made through the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan.
• The price per share was $28.2115.
• Following the transaction, Geary directly owns 99,492 shares of Ionis Pharmaceuticals common stock.
• These shares may not be sold until August 28, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a routine stock purchase by an executive. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• Executive's participation in the employee stock purchase plan demonstrates confidence in the company.

Industry Context

Executive stock purchases are common and often viewed as a positive signal, indicating management's belief in the company's future prospects. However, the impact on the stock price is usually minimal unless the purchase is substantial or part of a larger trend.

Comparison to Industry Standards

• Executive compensation packages, including stock purchase plans, are standard practice in the pharmaceutical industry.
• Companies like Biogen, Alnylam Pharmaceuticals, and Vertex Pharmaceuticals also offer similar plans to their employees and executives.
• The number of shares purchased and the holding period are typical components of such plans, designed to align executive interests with long-term shareholder value.

Stakeholder Impact

• The stock purchase could have a slightly positive impact on shareholders as it signals confidence from an executive.

Key Dates